Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 50/100

Q4 2019 Redhill Biopharma Ltd Earnings Call Transcript

Mar 04, 2020 / 01:30PM GMT
Release Date Price: €155.2 (+1.57%)
Operator

Good day, and welcome to the RedHill Biopharma's Full Year 2019 Financial Results Conference Call. At this time, I would like to introduce to the conference call RedHill's CEO, Mr. Dror Ben-Asher; Micha Ben-Chorin, RedHill's CFO; Mr. Rick Scruggs, RedHill's Chief Commercial Officer; Mr. Gilead Raday, RedHill's Chief Operating Officer; and Mr. Guy Goldberg, RedHill's Chief Business Officer. Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.

Unidentified Company Representative

This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to RedHill's expectations regarding the timing of the commercial launch of Talicia; the closing of the acquisition of rights to Movantik and the funding of the nondilutive financing agreement with Healthcare Royalty Partners; the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing, progress and results of RedHill's research,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot